United States Anti-Obesity Prescription Drug Markets


Regular Price: USD 3,950.00

Special Price USD 2,765.00

30% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 2,765.00


Be the first to review this product

Table of Contents

United States Anti-Obesity Prescription Drug Markets, Executive SummaryIntroduction to the Anti-Obesity Prescription Drug MarketMarket OverviewObjectives and PurposeReport Scope and SegmentationReport Structure Prevalence of Overweight and Obesity in the U.S. Adult PopulationAnalysis of Market Engineering ResearchAnalysis of Market Engineering ResearchMajor TrendsDrivers Affecting the Anti-Obesity Prescription Drug MarketRestraints Affecting the Anti-Obesity Prescription Drug MarketReimbursement TrendsCompetitive AnalysisAlliances, Acquisitions, and Licensing AgreementsStrategies for SuccessUnited States Anti-Obesity Prescription Drug Markets, Market Engineering Research MethodologyResearch ScopeObjectives and PurposeReport Structure and Market SegmentationMarket Engineering Forecasting MethodologyOverviewStrategic Significance of the Market Engineering ForecastJudging Credibility and Accuracy of Market Engineering ForecastsForecast AssumptionsUnited States Anti-Obesity Prescription Drug Markets, Industry ChallengesIdentification of Challenges Facing the Anti-Obesity Prescription Drug IndustryIdentification of Challenges Facing the Anti-Obesity Prescription Drug IndustryConvincing Physicians on the Merits of Anti-Obesity Drugs Drives Market GrowthConvincing Healthcare Providers to Reimburse Prescription Anti-Obesity Drugs Will Stimulate Market Penetration for New ProductsThe Need for Effective Drugs Forces R&D InnovationsEstablishing a Long-Term Drug Efficacy Profile for Weight Maintenance Is Necessary for Continued Market GrowthImproving Drug Side Effect Profile Ensures Persistent Drug UtilizationEducating the General Public on theBenefits of Physician-Mediated Prescription Drug-Use Over Non-Prescription Therapy Nurtures Overall Market HealthIncreasing Patient Retention Rates for Anti-Obesity Drugs Enhances Market ExpansionDemonstrating Superior Value Over Generic Phentermine Bolsters New Product AcceptanceProcuring Resources for Marketing Is Necessary for New Product IntroductionReversing Negative Perceptions of Anti-Obesity Drugs Facilitates Prescription Drug AcceptanceMarket Engineering Research for the Anti-Obesity Prescription Drug Market 1998-2006Market Overview and DefinitionsMarket OverviewMarket DefinitionDisease OverviewScope/SegmentationHistory of Anti-Obesity DrugsProduct OverviewMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket DriversNew Products Rejuvenate the MarketMagnitude and Increasing Growth Trend of the Overweight and Obese Population Creates Tremendous Market OpportunityModest Weight-Loss Provides Significant Health Benefits, Bolstering the Need for Drug TreatmentsAcceptance of Obesity as a Chronic Disease Necessitates Long-Term Treatment ApproachDirect-to-Consumer Marketing Increases Awareness of Benefits of PharmacotherapyAnti-Obesity Drugs May Have Positive Effects on Other Risk FactorsOff-Label Use of Prescription Drugs Stimulates Market GrowthIncreased Awareness of Obesity-Related Healthcare Costs May Force Acceptance of Pharmacotherapy by Healthcare ProvidersProgress in the Genetic Understanding of Obesity Spurs DemandDemand for “Cosmetic” Weight Loss Buoys Overall Market HealthMarket RestraintsMarket RestraintsOverweight and Obese Patients Do Not Consider Their Excess Weight as a Health RiskPhysicians Are Reluctant to Address Obesity with Their PatientsFailure to Gain Acceptance by Providers and Payors Severely Limits Market PenetrationEffectiveness of Fen/PhenCombination Raises Patient’s Expectations for New ProductsHigh Cost Limits Adoption of New DrugsShift from Physician-Controlled Prescription Drug Therapy to Self-Medication Stifles MarketPoor End-User Compliance with Treatment Regimen Limits Market PotentialInapplicability of Anti-Obesity Drugs to Overweight Patients Without Co-Morbidities Restricts Market GrowthOne Month Run-in Period, Which Is Indicative of Drug Effectiveness, Limits Market ExpansionLack of Established Guidelines for the Treatment of Obesity Restricts Overall Adoption of PharmacotherapyMarket Engineering and Revenue Forecasts (1998-2006)Cost AnalysisRevenuesMarket TrendsPricing TrendsReimbursement TrendsDemographic TrendsCompetitive AnalysisCompetitive AnalysisMarketing Messages for Meridia and XenicalDifferences in Indications and Contraindications Between Meridia and XenicalEffects of Meridia and Xenical on Metabolic ParametersContinual Assessment of Meridia and Xenical in Clinical StudiesCompetitive StructureAlliances, Acquisitions, and LicensingMarket Share AnalysisMarket Share Winner and WhyMarket Share Loser and WhyProducts in Clinical TrialsUnited States Anti-Obesity Prescription Drug Markets, Research Activities in the Anti-Obesity Therapy Market, 1999OverviewOverviewAppetite SuppressantsAppetite SuppressantsLeptinStimulator of the Leptin PromoterLeptin Receptor AgonistModulator of Leptin SignalingCiliary Neurotrophic Factor (CNTF)Neuropeptide Y (NPY) Receptor AntagonistPOMC/a-MSHAGRP (Agouti-related Peptide)Melanin-Concentrating Hormone (MCH)/SLC-1 ReceptorMelanocortin-4 Receptor (MC4-R) AgonistCorticotropin Releasing Factor (CRF) Receptor AgonistsGalanin Receptor AntagonistOrexin Receptor AntagonistCholecystokinin-A (CCK-A) Receptor AgonistGlucagon-like Protein-1 (GLP-1) Receptor AgonistCannaBinoid Receptor AntagonistCART (Cocaine and Amphetamine Regulated Transcript)Serotonin Receptor AgonistThyroid Hormone Receptor Beta AgonistTopiramateP57 (Plant-Based Appetite Suppressant)Enhancers of Energy ExpenditureEnhancers of Energy Expenditureß3-Adrenergic Receptor AgonistUncoupling ProteinsGrowth Hormone Receptor AgonistModulators of Fat MobilizationModulators of Fat MobilizationPeroxisome Proliferator-Activated-Receptors Gamma2 (PPAR-gamma2)Fatty Acid Transport Protein-4 (FATP4)Lipase InhibitorEnterostatin AgonistImmunological TherapyGenes Identified from Rodent Models of ObesityGenes Identified from Rodent Models of ObesitymahoganytubbeaconProhormone Convertase-1Treatments Developed for DiabetesTreatments Developed for DiabetesFuture Technology OutlookFuture Technology OutlookThe Prospects for Leptin TherapyThe Prospects of Modulating Downstream Targets of Leptin SignalingThe Prospects of Regulating Thermogenesis Through ß3-AR and Uncoupling ProteinsFailed Compounds in Clinical TrialsFuture Challenges United States Anti-Obesity Prescription Drug Markets, Clinical Perspective of Pharmacotherapy for Obesity Analysis of Clinical PracticeAnalysis of Clinical PracticeDiagnosis of ObesityDemand AnalysisCurrent Clinical PracticesFuture Trends in Clinical PracticeFuture Trends in Clinical PracticeMetabolic Fitness as a Result of Drug TherapyUnited States Anti-Obesity Prescription Drug Markets, Strategies for SuccessIntroductionIntroductionAccessing Technology Through Strategic Alliances and Licensing AgreementsAccessing Technology Through Strategic Alliances and Licensing AgreementsDefend your InnovationsDefend your InnovationsEnsure Reimbursement Through AwarenessEnsure Reimbursement Through AwarenessDevelop Physician Education Programs to Increase Market PenetrationDevelop Physician Education Programs to Increase Market PenetrationFocus Marketing on Patient-Centric CareFocus Marketing on Patient-Centric CareMarket Engineering Awards for the Anti-Obesity Prescription Drug MarketFrost & Sullivan's 1999 Market Engineering AwardsFrost & Sullivan's 1999 Market Engineering AwardsMarket Engineering AwardsMarket Engineering AwardsAward Category: Marketing StrategyAward Category: Product Differentiation Award Category: Merger & Acquisition Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.